|
GSK starts big African
study of injectable drug to prevent HIV
Send a link to a friend
[November 30, 2017] (Reuters)
- ViiV Healthcare, GlaxoSmithKline Plc's
HIV unit, said on Thursday it started an African study to evaluate
long-acting injectable drug for the prevention of HIV infection in
sexually active women.
|
|
 The cabotegravir study seeks to enrol 3,200 women aged 18 to 45
years from sub-Saharan African countries, ViiV Healthcare said in a
statement.
The HPTN 084 Phase III study will evaluate injections given every
two months, ViiV Healthcare said.
The study is being conducted through a public-private funding by
ViiV Healthcare, the National Institute of Allergy and Infectious
Diseases (NIAID), part of the National Institutes of Health (NIH),
and the Bill & Melinda Gates Foundation, the company said.
Viiv Healthcare in 2016 had started a large study on HIV-uninfected
men and transgender women who have sex with men to test an
experimental long-acting injection for preventing the virus that
causes AIDS.
[to top of second column] |
(Reporting by Subrat Patnaik in Bengaluru; Editing by Akshay Lodaya)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
